No Data
No Data
Citigroup: Gives a 'buy' rating to Pharmaron (02268) with a target price of HKD 41.
Citigroup initiates a 30-day bullish observation on Joinn Laboratories (02268).
Citigroup has initiated a 30-day bullish observation on WuXi AppTec (02268.HK) in Da Hang.
According to Citigroup's report, due to strong demand for WuXi Biologics' (02268.HK) projects, it is expected to achieve ideal performance in the first half of the year, with a year-on-year profit increase of 57%, while the market predicts a growth of 48%. In addition, management also indicated that the order trend is good. Citigroup has launched a 30-day upward catalytic observation on WuXi Biologics with a target price of HKD 41 and a rating of "buy".
Nomura Adjusts WuXi XDC Cayman's Price Target to HK$28.91 From HK$32.52, Keeps at Buy
Dah Sing raised the target price of Nomura to 28.91 yuan, reflecting market volatility and geopolitical uncertainty.
Nomura's report states that under strong demand for the anti-body drug conjugate (ADC) model at home and abroad, it is expected that WuXi Biologics (02268.HK) will achieve strong revenue and profit growth in the first half of the year, with an annual increase of 44.3% and 45.3%, reaching a revenue of up to 1.43 billion RMB. The bank maintains its 'buy' rating on WuXi Biologics, with a target price lowered from 32.52 yuan to 28.91 yuan, reflecting market volatility and geopolitical uncertainty. Considering the high demand from customers for the company's ADC contract research, development and manufacturing organization (CRDMO), the bank maintains its 2024 and 2025 outlook.
Some Hong Kong biotechnology stocks fell.
On July 16th, Gelonghui reported that Yongtai Biotechnology dropped more than 5%, Pharmaron fell more than 4%, and Pharmaron Jinuo fell more than 2%.
WuXi XDC Issues Restricted Shares to Staff
No Data